Compare AbCellera Biologics Inc (ABCL) vs United Microelectronics Corp (UMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs United Microelectronics Corp — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while United Microelectronics Corp trades at $24.75 (market cap $60.80B). The key difference: United Microelectronics Corp is far larger — about 25.9× AbCellera Biologics Inc's market cap, and United Microelectronics Corp pays a 1.73% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | UMC | |
|---|---|---|
Market Cap | $2.35B | $60.80B |
Sector | Health | Technology |
52-Week High | $8.12 | $28.02 |
52-Week Low | $2.78 | $6.58 |
Enterprise Value | $1.99B | $58.38B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
UMC trades at $23.83, down 2.89% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $237.55 billion in 2025, though net income margin compressed to 16.99%. The company maintains strong cash flow from operations and announced a $0.41 dividend for H2-26, reflecting financial stability amid competitive semiconductor market dynamics.
Outlook remains supported by specialty chip demand and 14nm eHV platform innovation, but valuation multiples like P/E of 41.94 suggest premium pricing. Risks include margin pressure and industry cyclicality, while analyst consensus leans hold with 53.33% neutral ratings, indicating cautious optimism for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
